Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
CORT 34.79 +0.51(1.49%)
Will CORT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Other News for CORT
Buy Rating Affirmed for Corcept Therapeutics on Strong Financials and Promising Drug Pipeline
ClearBridge Small Cap Value Strategy Q2 2024 Commentary
And Just Like That, Recession Enters The Chat
Biotech Alert: Searches spiking for these stocks today
Corcept Therapeutics price target raised by $40 at Canaccord, here's why